Results 111 to 120 of about 5,148 (157)

Chronic Hepatitis B: Current Management and Future Directions. [PDF]

Diseases
Ertugrul H, Ekiz E, Islak Mutcali S, Tahan V, Daglilar E.   +4 more
europepmc   +1 more source

Flavonoid Interactions with Renal Organic Anion Transporters OAT1 and OAT3: Structure-Activity Relationships and Clinical Implications. [PDF]

Int J Mol Sci
Tong K, Ye P, Kaneda-Nakashima K, Zhang H, Wei L.   +4 more
europepmc   +1 more source

Impact of Allostatic Load on Chronic Hepatitis B and C: A Narrative Review. [PDF]

Cureus
Ogbu CE, Kalu JN, Ezechukwu M, Umerah C.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Adefovir Dipivoxil

Drugs, 1999
Adefovir dipivoxil is an ester prodrug of the nucleoside reverse transcriptase inhibitor adefovir (PMEA), the prototype compound of the acyclic nucleoside phosphonates. It has better oral bioavailability than the parent compound. Adefovir dipivoxil 120mg once daily significantly reduced viral load compared with placebo when added to standard ...
S, Noble, K L, Goa
openaire   +2 more sources

Adefovir dipivoxil

Drugs of Today, 2003
In chronic hepatitis B therapy there are new and exciting developments in antivirals such as nucleotide analogues. Adefovir is the latest drug approved for therapy of chronic hepatitis B. This agent has a potent in vitro and in vivo effect against herpes virus, retroviruses and hepadnaviruses.
María, Buti, Rafael, Esteban
openaire   +2 more sources

Adefovir

Reactions Weekly, 2021
  +4 more sources

Adefovir

Reactions Weekly, 2017
  +5 more sources

Adefovir

Reactions Weekly, 2015
  +5 more sources